Aquestive Therapeutics, Inc. — Form 10-Q
Filed November 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Aquestive Therapeutics entered into a license agreement dated September 18, 2026 with Helix NB LLC for 4,993 sq ft of wet lab and office space (Suite D, 10th floor) at H-1 @ New Jersey Health + Life Science Exchange in New Brunswick, NJ. Fixed license fees: Year 1: $249,650 ($20,804/month); Year 2: $257,139.50 ($21,428/month); Year 3: $264,853.69 ($22,071/month). Security deposit: $62,412.51. Three-year initial term with one optional 36-month renewal at fair market value. Possession date targeted prior to September 30, 2026. Licensee pays proportionate share (3.62%) of operating costs and utilities; landlord provides HVAC, electricity, water, lab-specific infrastructure (acid neutralization, RO/DI water, fume hood exhaust), and 24/7 security.
Why this rating
Routine real estate transaction; ~$772k over 3 years is ~0.26% of $291.6M market cap. Modest facility upgrade, not transformational. Supports ongoing operations but minor relative to company scale.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.